Multimodal therapy including robot‐assisted radical cystoprostatectomy for locally advanced prostate cancer with bladder and ureteral invasion: A case report

It remains unclear whether robot‐assisted radical cystoprostatectomy for locally advanced prostate cancer represents excessive treatment.

[1]  F. Montorsi,et al.  Contemporary role of palliative cystoprostatectomy or pelvic exenteration in advanced symptomatic prostate cancer , 2020, World Journal of Urology.

[2]  T. Bathala,et al.  Management of cT4 Prostate Cancer. , 2020, European urology focus.

[3]  Z. Ye,et al.  The role of cystoprostatectomy in management of locally advanced prostate cancer: a systematic review , 2020, World journal of surgical oncology.

[4]  Z. Ye,et al.  Quality of life among patients after cystoprostatectomy as the treatment for locally advanced prostate cancer with bladder invasion , 2019, The aging male : the official journal of the International Society for the Study of the Aging Male.

[5]  T. Nakatani,et al.  Time to progression to castration-resistant prostate cancer after commencing combined androgen blockade for advanced hormone-sensitive prostate cancer , 2018, Oncotarget.

[6]  F. Schumacher,et al.  Comparative Effectiveness of Local and Systemic Therapy for T4 Prostate Cancer. , 2018, Urology.

[7]  K. Haustermans,et al.  The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer , 2017, Prostate Cancer and Prostatic Diseases.

[8]  Isla P. Garraway,et al.  Impact of treatment on progression to castration‐resistance, metastases, and death in men with localized high‐grade prostate cancer , 2016, Cancer medicine.

[9]  T. Habuchi,et al.  Cystoprostatectomy as a Treatment of Prostate Cancer Involving the Bladder Neck , 2009, Urologia Internationalis.

[10]  C. Logothetis,et al.  Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer. , 2005, The Journal of urology.

[11]  H. Kanetake,et al.  Relationship between changes in prostate cancer cell proliferation, apoptotic index, and expression of apoptosis-related proteins by neoadjuvant hormonal therapy and duration of such treatment. , 2005, Urology.

[12]  P. Pisters,et al.  Total pelvic exenteration: effective palliation of perineal pain in patients with locally recurrent prostate cancer. , 2003, The Journal of urology.

[13]  M. Gleave,et al.  Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. , 2001, The Journal of urology.